Business · 17/10/2016Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Sarepta Therapeutics for Rare Pediatric Disease Product EXONDYS 51
Summary
The FDA has issued a priority review voucher to Sarepta Therapeutics for its rare pediatric disease product EXONDYS 51, which is manufactured by the company and is used to treat Duchenne muscular dystrophy.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →